<DOC>
	<DOC>NCT00551148</DOC>
	<brief_summary>The purpose of this study is to further explore an effective dose range of PD0200390 for the treatment of patients with insomnia.</brief_summary>
	<brief_title>A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<criteria>3 month history of Primary Insomnia (DSMIV criteria) Self report sleep criteria for at least 3 nights per week in past month; sWASO (subjective wake after sleep onset) equal or greater than 60 mins sLSO (subjective latency to sleep onset) equal or greater than 45 minutes TST less than or equal to 6.5 hrs Maintain normal daytimeawake, nighttimesleep schedule PSG sleep criteria of mean WASO equal or greater than 60 mins calculated on 2 PSG screening nights TST between 3 to 7 hrs on 2 PSG screening nights Mean LPS (latency to persistent sleep) equal or greater than 20 mins calculated on 2 PSG screening nights Comorbid psychiatric disease or disorders History or presence of breathingrelated disorders Multivariable Apnea risk index (MAP) equal or greater than 0.5 at screening History or presence of medical or neurological condition interfering with sleep Current use of know psychotropic effect medications Excessive caffeine use Use of alcohol as a sleep aid or more than 2 standard drinks/day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>